Issues of prematurity and HIV infection

Clinics in Perinatology

Volumn 37, Issue 4, 2010, Pages 887-905

  Mirpuri, Julie ^a   Jain, Lucky ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Cesarean delivery; HIV; Late preterm; Perinatal transmission; Premature infant; Preterm birth

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANEMIA; BREAST FEEDING; CESAREAN SECTION; COMBINATION CHEMOTHERAPY; COUNSELING; DELIVERY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; EARLY DIAGNOSIS; EARLY INTERVENTION; FEMALE GENITAL TRACT INFECTION; FETUS DEATH; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; INFECTION PREVENTION; LACTIC ACIDOSIS; MONOTHERAPY; MULTIPLE ORGAN FAILURE; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PERINATAL INFECTION; PREECLAMPSIA; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; TERATOGENICITY; VERTICAL TRANSMISSION; VIREMIA; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; POPULATION SURVEILLANCE; VACCINATION;

EID: 78349247078     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2010.08.012     Document Type: Review

References (72)

1. Achievements in public health Reduction in perinatal transmission of HIV infection-United States, 1985-2005. MMWR Morb Mortal Wkly Rep 2006, 55:592-597.
2. Kumar R.M., Uduman S.A., Khurranna A.K. Impact of maternal HIV-1 infection on perinatal outcome. Int J Gynaecol Obstet 1995, 49:137-143.
3. Leroy V., Ladner J., Nyiraziraje M., et al. Effect of HIV-1 infection on pregnancy outcome in women in Kigali, Rwanda, 1992-1994. Pregnancy and HIV Study Group. AIDS 1998, 12:643-650.
4. Temmerman M., Chomba E.N., Ndinya-Achola J., et al. Maternal human immunodeficiency virus-1 infection and pregnancy outcome. Obstet Gynecol 1994, 83:495-501.
5. Ramachandrappa A., Jain L. Health issues of the late preterm infant. Pediatr Clin North Am 2009, 56:565-577.
6. Aebi-Popp K., Lapaire O., Glass T.R., et al. Pregnancy and delivery outcomes of HIV infected women in Switzerland 2003-2008. J Perinat Med 2010, 38(4):353-358.
7. Lindegren M.L., Byers R.H., Thomas P., et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 1999, 282:531-538.
8. Centers for Disease Control and Prevention. Cases of HIV infection and AIDS in the United States and dependent areas, 2007. Available at: Accessed August 18, 2010. http://www.cdc.gov/hiv/surveillance/resources/reports/2007report/.
9. Cooper E.R., Charurat M., Mofenson L., et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002, 29:484-494.
10. Connor E.M., Sperling R.S., Gelber R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180.
11. Brocklehurst P., French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 1998, 105:836-848.
12. Traisathit P., Mary J.Y., Le Coeur S., et al. Risk factors of preterm delivery in HIV-infected pregnant women receiving zidovudine for the prevention of perinatal HIV. J Obstet Gynaecol Res 2009, 35:225-233.
13. Tuntiseranee P., Olsen J., Chongsuvivatwong V., et al. Socioeconomic and work related determinants of pregnancy outcome in southern Thailand. J Epidemiol Community Health 1999, 53:624-629.
14. Martin R., Boyer P., Hammill H., et al. Incidence of premature birth and neonatal respiratory disease in infants of HIV-positive mothers. The Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted Human Immunodeficiency Virus Infection Study Group. J Pediatr 1997, 131:851-856.
15. Racial/ethnic disparities in diagnoses of HIV/AIDS-33 states, 2001-2005. MMWR Morb Mortal Wkly Rep 2007, 56:189-193.
16. Epidemiology of HIV/AIDS-United States, 1981-2005. MMWR Morb Mortal Wkly Rep 2006, 55:589-592.
17. De Cock K.M., Fowler M.G., Mercier E., et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000, 283:1175-1182.
18. Anderson B.L., Cu-Uvin S. Pregnancy and optimal care of HIV-infected patients. Clin Infect Dis 2009, 48:449-455.
19. Branson B.M., Handsfield H.H., Lampe M.A., et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006, 55:1-17. [quiz: CE11-4].
20. Sansom S.L., Jamieson D.J., Farnham P.G., et al. Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission. Obstet Gynecol 2003, 102:782-790.
21. Nurutdinova D., Overton E.T. A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV. Expert Opin Drug Saf 2009, 8:683-694.
22. Suy A., Martinez E., Coll O., et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006, 20:59-66.
23. Visnegarwala F., Krause K.L., Musher D.M. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997, 127:947.
24. Eastone J.A., Decker C.F. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997, 127:948.
25. Chmait R., Franklin P., Spector S.A., et al. Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance. J Perinatol 2002, 22:370-373.
26. Dinsmoor M.J., Forrest S.T. Lack of an effect of protease inhibitor use on glucose tolerance during pregnancy. Infect Dis Obstet Gynecol 2002, 10:187-191.
27. Tang J.H., Sheffield J.S., Grimes J., et al. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet Gynecol 2006, 107:1115-1119.
28. Recommendations for use of antiretroviral drugs in pregnant HIV-1-Infected women for maternal health and Interventions to reduce perinatal HIV transmission in the United States. 2010. Available at: Accessed August 18, 2010. http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf.
29. Wimalasundera R.C., Larbalestier N., Smith J.H., et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002, 360:1152-1154.
30. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000, 14:2913-2920.
31. Tuomala R.E., Shapiro D.E., Mofenson L.M., et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002, 346:1863-1870.
32. Patel K, Shapiro DE, Brogly SB, et al. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis 2010;201:1035-44.
33. Kourtis A.P., Schmid C.H., Jamieson D.J., et al. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007, 21:607-615.
34. Steer P. The epidemiology of preterm labor-a global perspective. J Perinat Med 2005, 33:273-276.
35. Barros F.C., Victora C.G., Barros A.J., et al. The challenge of reducing neonatal mortality in middle-income countries: findings from three Brazilian birth cohorts in 1982, 1993, and 2004. Lancet 2005, 365:847-854.
36. Barret B., Tardieu M., Rustin P., et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003, 17:1769-1785.
37. Lewis W. Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions. Antiviral Res 2003, 58:189-197.
38. Noguera A., Fortuny C., Munoz-Almagro C., et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004, 114:e598-e603.
39. Divi R.L., Walker V.E., Wade N.A., et al. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS 2004, 18:1013-1021.
40. Divi R.L., Leonard S.L., Kuo M.M., et al. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Environ Mol Mutagen 2007, 48:201-209.
41. Blanche S., Tardieu M., Rustin P., et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999, 354:1084-1089.
42. Brogly S.B., Ylitalo N., Mofenson L.M., et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 2007, 21:929-938.
43. Poirier M.C., Divi R.L., Al-Harthi L., et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003, 33:175-183.
44. Le Chenadec J., Mayaux M.J., Guihenneuc-Jouyaux C., et al. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003, 17:2053-2061.
45. Bunders M.J., Bekker V., Scherpbier H.J., et al. Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr 2005, 94:1571-1577.
46. Joao EC, Calvet GA, Krauss MR, et al. Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study. J Acquir Immune Defic Syndr 2010;53:176-85.
47. Garcia P.M., Kalish L.A., Pitt J., et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999, 341:394-402.
48. Ioannidis J.P., Abrams E.J., Ammann A., et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis 2001, 183:539-545.
49. ACOG committee opinion scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. Number 234, May 2000 (replaces number 219, August 1999). Int J Gynaecol Obstet 2001, 73:279-281.
50. European Collaborative Study Group. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005, 40:458-465.
51. International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS 2001, 15:357-368.
52. Garcia-Tejedor A., Perales A., Maiques V. Duration of ruptured membranes and extended labor are risk factors for HIV transmission. Int J Gynaecol Obstet 2003, 82:17-23.
53. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004, 11(Suppl 1):24A-35A.
54. Baeten J.M., McClelland R.S., Corey L., et al. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis 2004, 189:1466-1471.
55. Mbopi-Keou F.X., Legoff J., Gresenguet G., et al. Genital shedding of herpes simplex virus-2 DNA and HIV-1 RNA and proviral DNA in HIV-1- and herpes simplex virus-2-coinfected African women. J Acquir Immune Defic Syndr 2003, 33:121-124.
56. Mole L., Ripich S., Margolis D., et al. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997, 176:766-770.
57. Lingappa JR, Baeten JM, Wald A, et al. Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010;375:824-33.
58. Chen K.T., Segu M., Lumey L.H., et al. Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. Obstet Gynecol 2005, 106:1341-1348.
59. Lunney KM, Iliff P, Mutasa K, et al. Associations between breast milk viral load, mastitis, exclusive breast-feeding, and postnatal transmission of HIV. Clin Infect Dis 2010;50:762-9.
60. King S.M. Evaluation and treatment of the human immunodeficiency virus-1-exposed infant. Pediatrics 2004, 114:497-505.
61. McGuire W., Anthony M.Y. Donor human milk versus formula for preventing necrotising enterocolitis in preterm infants: systematic review. Arch Dis Child Fetal Neonatal Ed 2003, 88:F11-F14.
62. ACOG committee opinion number 304, November 2004 Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. Obstet Gynecol 2004, 104(5 Pt 1):1119-1124.
63. Bulterys M., Jamieson D.J., O'Sullivan M.J., et al. Rapid HIV-1 testing during labor: a multicenter study. JAMA 2004, 292:219-223.
64. Hepatitis C. virus infection. American Academy of Pediatrics. Committee on Infectious Diseases. Pediatrics 1998, 101(3 Pt 1):481-485.
65. Mofenson L.M. Technical report: perinatal human immunodeficiency virus testing and prevention of transmission. Committee on Pediatric Aids. Pediatrics 2000, 106. E88.
66. Mofenson L.M. U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep 2002, 51(RR-18):1-38. [quiz: CE31-4].
67. Van Rompay K.K., Otsyula M.G., Marthas M.L., et al. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrobial Agents Chemother 1995, 39:125-131.
68. Tsai C.C., Follis K.E., Sabo A., et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995, 270:1197-1199.
69. Bottiger D., Johansson N.G., Samuelsson B., et al. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS 1997, 11:157-162.
70. Schneider E., Whitmore S., Glynn K.M., et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years-United States, 2008. MMWR Recomm Rep 2008, 57(RR-10):1-12.
71. Recommended childhood immunization schedule-United States, 2002. MMWR Morb Mortal Wkly Rep 2002, 51:31-33.
72. Measles immunization in HIV-infected children. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Pediatric AIDS. Pediatrics 1999, 103(5 Pt 1):1057-1060.